DrugScience: Difference between revisions
CSV import |
CSV import |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 40: | Line 40: | ||
{{stub}} | {{stub}} | ||
{{No image}} | |||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 09:55, 17 March 2025
DrugScience is a UK-based scientific committee that conducts research on drugs and provides evidence-based information to the public. It was founded in 2010 by Professor David Nutt after his dismissal from his position as the UK government's chief drug advisor. DrugScience is a non-profit organization that relies on donations and grants for funding.
History[edit]
DrugScience was established in 2010 by Professor David Nutt following his dismissal from his position as the UK government's chief drug advisor. Nutt was dismissed after he criticized the government's decision to reclassify cannabis as a Class B drug. He argued that the decision was not based on scientific evidence, but on political considerations.
Mission[edit]
The mission of DrugScience is to provide the public with clear, evidence-based information on drugs and drug harm. The organization aims to promote a rational, evidence-based approach to drug policy and to reduce the harm caused by drugs.
Activities[edit]
DrugScience conducts research on a wide range of drugs, including cannabis, MDMA, psilocybin, and LSD. The organization also provides information on the risks and benefits of these drugs, and on the effects of different drug policies.
Funding[edit]
DrugScience is a non-profit organization that relies on donations and grants for funding. The organization does not accept funding from the pharmaceutical industry or from any other source that could compromise its independence.
Criticism[edit]
DrugScience has been criticized by some for its stance on drug policy. Some critics argue that the organization's focus on harm reduction and evidence-based policy overlooks the potential dangers of drug use.
See also[edit]
References[edit]
<references />


